Clinical Trial Update: Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating romidepsin plus erlotinib in stage III/IV non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• Romidepsin (romidepsin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Lung Cancer, Metastatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-01-20